Amedisys (AMED) & The Competition Critical Survey

Amedisys (NASDAQ:AMED) is one of 26 public companies in the “MED – OUTP/HM CRE” industry, but how does it weigh in compared to its peers? We will compare Amedisys to similar businesses based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Amedisys and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amedisys	0	4	1	0	2.20
Amedisys Competitors	107	900	1357	57	2.56

Amedisys currently has a consensus target price of $100.75, suggesting a potential upside of 2.89%. As a group, “MED – OUTP/HM CRE” companies have a potential upside of 23.90%. Given Amedisys’ peers stronger consensus rating and higher probable upside, analysts plainly believe Amedisys has less favorable growth aspects than its peers.

Volatility & Risk

Amedisys has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Amedisys’ peers have a beta of 1.18, indicating that their average stock price is 18% more volatile than the S&P 500.

Earnings & Valuation

This table compares Amedisys and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Amedisys	$2.35 billion	$43.23 million	36.13
Amedisys Competitors	$3.78 billion	$179.91 million	21.21

Amedisys’ peers have higher revenue and earnings than Amedisys. Amedisys is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

94.4% of Amedisys shares are held by institutional investors. Comparatively, 71.8% of shares of all “MED – OUTP/HM CRE” companies are held by institutional investors. 2.1% of Amedisys shares are held by company insiders. Comparatively, 9.9% of shares of all “MED – OUTP/HM CRE” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Amedisys and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amedisys	3.79%	12.52%	7.01%
Amedisys Competitors	-12.27%	-0.50%	-4.12%

Summary

Amedisys peers beat Amedisys on 8 of the 13 factors compared.

About Amedisys

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer’s. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.